Aduro BioTech Inc (ADRO) Releases Earnings Results, Beats Expectations By $0.21 EPS

Aduro BioTech Inc (ADRO) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $0.03 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.21. Analysts had a consensus of $-0.18. The company posted revenue of $39.00 million in the period, compared to analysts expectations of $25.24 million. The company’s revenue was up 306.3% compared to the same quarter last year.

Many Wall Street Analysts have commented on Aduro BioTech Inc. Shares were Reiterated by FBR Capital on May 17, 2016 to “Outperform” and Lowered the Price Target to $ 22 from a previous price target of $30 .

Aduro BioTech Inc closed down -0.38 points or -2.56% at $14.46 with 4,02,101 shares getting traded on Tusday. Post opening the session at $14.87, the shares hit an intraday low of $14.19 and an intraday high of $14.9 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jul 7, 2016, Thomas W. Dubensky (Chief Scientific Officer) sold 25,000 shares at $11.61 per share price. According to the SEC, on May 18, 2016, Dirk G. Brockstedt (Sr. VP of Research and Dev.) sold 905 shares at $8.20 per share price. On May 18, 2016, Gregory W Schafer (Chief Operating Officer) sold 905 shares at $8.20 per share price, according to the Form-4 filing with the securities and exchange commission.

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live attenuated Listeria GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207 ADU-623 ADU-214 ADU-741 CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.

Aduro BioTech Inc

Leave a Reply

Aduro BioTech Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aduro BioTech Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.